ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas [1]

International Journal of Cancer

Volumn 119, Issue 12, 2006, Pages 2986-2987

  Eun, Goo Jeong ^a   Young, Hwa Soung ^a   Jong, Woo Lee ^a   Sung, Hak Lee ^a   Suk, Woo Nam ^a   Jung, Young Lee ^a   Nam, Jin Yoo ^a   Sug, Hyung Lee ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; PROTEIN TYROSINE KINASE;

AMINO ACID SUBSTITUTION; BREAST CARCINOMA; COLON CARCINOMA; DNA SEQUENCE; GENE MUTATION; HUMAN; HUMAN TISSUE; LETTER; LUNG CARCINOMA; MISSENSE MUTATION; MUTATION RATE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SILENT MYOCARDIAL INFARCTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

ADENOCARCINOMA; BASE SEQUENCE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CATALYTIC DOMAIN; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MUTATION; MUTATION, MISSENSE; NEOPLASM STAGING; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTOR, ERBB-3;

EID: 33751573874     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22257     Document Type: Letter

References (9)

1. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
3. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48.
4. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004;431:525,526.
5. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, et al. Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clin Cancer Res 2006;12:57-61.
6. Soung YH, Lee JW, Kim SY, Wang YP, Jo KH, Moon SW, Park WS, Nam SW, Lee JY, Yoo NJ, Lee SH. Somatic mutations of the ERBB4 kinase domain in human cancers. Int J Cancer 2006;118:1426-9.
7. Stephens P, Edkins S, Davies H, Greenman C, Cox C, Hunter C, Bignell G, Teague J, Smith R, Stevens C, O'Meara S, Parker A, et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 2005;37:590-2.
8. Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G, Teague J, Butler A, Edkins S, Stevens C, Parker A, O'Meara S, et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005;65:7591-5.
9. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL, III. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 1994;91;8132-4.